Litigation Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2021)
✉ Email this page to a colleague
Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2021)
| Docket | ⤷ Start Trial | Date Filed | 2021-02-16 |
| Court | District Court, D. Delaware | Date Terminated | 2021-04-16 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | PF PRISM C.V. | ||
| Patents | 10,639,309; 6,965,027; RE41,783 | ||
| Attorneys | Jack B. Blumenfeld | ||
| Firms | Morris, Nichols, Arsht & Tunnell | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-02-16 | External link to document | |||
| 2021-02-15 | 1 | Complaint | United States Patent No. RE41,783 (“the RE’783 patent”) and United States Patent No. 6,965,027 (“the ’027…for the RE’783 patent as December 8, 2025, and the expiration date for the ’027 patent as March 25, 2023… additional patent for the 22 mg strength of Xeljanz XR that is not at issue: U.S. Patent No. 10,639,…2034. The RE’783 Patent 23. On September 28, 2010, the United States Patent and Trademark …issued the RE’783 patent, titled “Pyrrolo[2,3-d]pyrimidine Compounds.” The RE’783 patent is a reissue of | External link to document |
| 2021-02-15 | 3 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,965,027 B2 ;RE41,783 E. (apk…2021 16 April 2021 1:21-cv-00214 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
